Business Standard

Monday, February 10, 2025 | 12:14 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Zydus Cadila's Baddi facility receives US FDA nod

The company has also received US FDA approval for anti-depressant drug, mirtazapine

Zydus acquires derma brand Melgain from Issar Pharma
Premium

BS B2B Bureau Ahmedabad
Zydus Cadila's formulations manufacturing facility at Baddi (Himachal Pradesh) has received the establishment inspection report (EIR) from the US Food & Drug Administration (FDA). “The company’s formulations manufacturing facility at Baddi has received an establishment inspection report from the US FDA. This receipt of EIR indicates the successful closure of the inspection points (483s) raised based on the inspection carried out between February 21, 2017 to March 1, 2017,” said Zydus Cadila in a press release.

Meanwhile, Zydus Cadila has received the final approval from the US FDA to market mirtazapine orally disintegrating tablets in strengths of 15 mg, 30

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in